BioVie Welcomes New Members to Board of Directors
BioVie Inc. (NASDAQ: BIVI), a pioneering clinical-stage company, announces the strategic appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors. This decision comes as the company continues to innovate in the treatment of neurological and neurodegenerative disorders, including early Parkinson's disease and long COVID.
Expertise and Vision for Change
Cuong Do, President and CEO of BioVie, emphasized the significance of these appointments. Both Amy and Kameel are esteemed individuals whose backgrounds in drug development and commercialization bring a wealth of knowledge to BioVie. Their collective experience is crucial as the company accelerates its efforts in clinical development, particularly with its promising candidate, bezisterim.
Amy S. Chappell: A Wealth of Experience
Dr. Chappell's extensive experience in clinical neuroscience spans over two decades. During her impressive tenure at Eli Lilly & Co., she was instrumental in the development and FDA approvals of vital therapies, significantly impacting patients suffering from chronic conditions. As the Chief Medical Officer at Solaxa Inc., her strategic insights continue to shape the development of innovative therapies.
Kameel D. Farag: A Proven Track Record
With a robust background in global finance, Mr. Farag previously served as Chief Financial Officer at Aspen Neuroscience, where he facilitated significant growth and capital acquisition. His financial acumen will prove invaluable as BioVie embarks on the next chapter of its clinical development journey.
Current Clinical Developments and Future Plans
BioVie is currently advancing its Phase 2 trials for bezisterim while preparing further clinical studies for Alzheimer's disease and ascites. The recent data presented at renowned conferences highlights bezisterim's potential in addressing neurodegeneration, making BioVie a company to watch in the biopharmaceutical domain.
Upcoming Clinical Trials
The launch of the ADDRESS-LC trial focused on long COVID marks another milestone for BioVie. This initiative exemplifies the company's commitment to patient-centered clinical innovation. Their ongoing SUNRISE-PD study represents vital steps in Parkinson's disease research.
About BioVie Inc.
BioVie is dedicated to creating transformative therapies specifically targeting neurological disorders and advanced liver disease. Their drug candidate, bezisterim, operates by modulating inflammatory responses that contribute to conditions like Alzheimer’s and Parkinson’s disease. Furthermore, BioVie’s orphan drug candidate BIV201 is under FDA Fast Track designation, signaling a promising future in liver disease treatment.
Frequently Asked Questions
What recent appointments have been made to BioVie’s Board?
Amy S. Chappell and Kameel D. Farag have joined the Board of Directors of BioVie Inc.
What is BioVie’s primary focus?
BioVie focuses on developing innovative therapies for neurological disorders and advanced liver diseases.
What is bezisterim?
Bezisterim is BioVie’s drug candidate aimed at mitigating neuroinflammation and helping in conditions related to Alzheimer’s and Parkinson’s diseases.
What trials is BioVie currently conducting?
BioVie is conducting Phase 2 trials for bezisterim and trials for long COVID and Parkinson’s disease.
Where can I find more information about BioVie?
For additional details, you can visit BioVie’s official website.
